



13 March 2024

ASX Announcement
SHAREHOLDER TOWN HALL WEBINAR

InhaleRx Ltd (ASX: IRX), (“**InhaleRx**”, “**IRX**” or “**the Company**”) an Australian healthcare company developing unique inhaled medicinal drug-device products to address unmet medical needs in pain management and mental health sectors, is pleased to invite shareholders to a webinar on Wednesday, 20 March 2024, commencing at 1.30pm AEDT.

The webinar will provide an update on progress with the Company’s clinical development program.

To access the webinar, please use the following link:

<https://us02web.zoom.us/j/88964902121?pwd=ZEpxS1FWT0Z3Sk1NnlFWkdHMEp1QT09>

Shareholders are encouraged to email any specific questions they would like addressed by 5pm AEDT on Tuesday, 19 March 2024 to: info@inhalerx.com.au

Those shareholders who are unable to attend are similarly encouraged to email their questions by the above closing date and time.

A copy of the presentation slides for the webinar will be lodged on the ASX immediately prior to the webinar commencing.

Authorised by the Board of Directors.

For further information:

James Barrie
Company Secretary
Phone +61 3 8678 4091
info@inhalerx.com.au
www.inhalerx.com.au

About InhaleRx Limited (ASX: IRX) – www.inhalerx.com.au

InhaleRx Limited is an Australian healthcare company which is developing unique medicinal drug-device products to address unmet medical needs in pain management and mental health sectors.

The overarching goal is to pursue U.S. FDA approval and registration using rapid and cost-effective regulatory pathways, such as 505(b)(2).

There is a significant economic opportunity for IRX and the Company's shareholders, the first medical indications under investigation and Breakthrough Cancer Pain ('**BTcP**') and Panic Disorder ('**PD**'), both of which currently have limited safe and effective treatment options.

IRX holds an innovation patent and provisional patents for the nominated indications and the Company plans to continue to strengthen this position.